Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Baxter
Mallinckrodt
Harvard Business School
Merck
Colorcon
AstraZeneca

Last Updated: November 22, 2019

DrugPatentWatch Database Preview

Details for Patent: 7,198,801

See Plans and Pricing

« Back to Dashboard

Summary for Patent: 7,198,801
Title:Formulations for transdermal or transmucosal application
Abstract:The present invention relates generally to formulations for transdermal or transmucosal administration of an active agent. The invention is a substantially malodorous-free and irritation free transdermal formulation which is substantially free of long chain fatty alcohols, long-chain fatty acids, and long-chain fatty esters.
Inventor(s): Carrara; Dario Norberto R. (Oberwil, CH), Grenier; Arnaud (Steinbrunn le Haut, FR), Besse; Celine (Saint Louis, FR), Simes; Stephen M. (Long Grove, IL), Lehman; Leah M. (Green Oaks, IL)
Assignee: Antares Pharma IPL AG (Zug, CH)
Application Number:10/798,161
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 7,198,801
Patent Claim Types:
see list of patent claims
Formulation; Compound; Delivery;

Drugs Protected by US Patent 7,198,801

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Mylan Speciality Lp ELESTRIN estradiol GEL, METERED;TRANSDERMAL 021813-001 Dec 15, 2006 RX Yes Yes   Start Trial   Start Trial Y   Start Trial
Allergan Sales Llc GELNIQUE 3% oxybutynin GEL, METERED;TRANSDERMAL 202513-001 Dec 7, 2011 DISCN Yes No   Start Trial   Start Trial Y   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Foreign Priority and PCT Information for Patent: 7,198,801

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
PCT/EP00/07533Aug 03, 2000

International Family Members for US Patent 7,198,801

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Argentina 030312   Start Trial
Austria 355854   Start Trial
Austria 356636   Start Trial
Austria 485837   Start Trial
Austria 534373   Start Trial
Australia 2001282064   Start Trial
Australia 2004220498   Start Trial
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Baxter
McKesson
Moodys
Johnson and Johnson
Boehringer Ingelheim
Merck

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.